Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:43:05.417Z.
Calculation as of: 2026-10-06T20:43:05.417Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2f5c47113f9c506e2e082fd2a1fe30760bd520268ada69101bb9e18573fa4dd9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$870.81M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$857.16M
Price/FCF Ratio
N/A
TTM Avg
104.86
3Y Avg
47.92
5Y Avg
28.61
Market Cap
$853.13M
Price/FCF Ratio
10.75
TTM Avg
9.59
3Y Avg
14.15
5Y Avg
25.73
Market Cap
$884.97M
Price/FCF Ratio
N/A
TTM Avg
27.25
3Y Avg
19.97
5Y Avg
19.97
Market Cap
$887.99M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $867.03M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | N/A | 104.86 | 47.92 | 28.61 |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 10.75 | 9.59 | 14.15 | 25.73 |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | N/A | 27.25 | 19.97 | 19.97 |
| Bioventus Inc. (BVS)vs › | $887.50M | 9.41 | 9.57 | 34.87 | 48.37 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | N/A | 198.42 | 198.42 | 198.42 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
